…NS is extremely rare, it is a severe and unmet need…
“I’m thrilled to receive this funding and am honored to be joined by Dr. Julia Oh at JAX for this research,” said Travis Whitfill, MPH, Founder and Chief Scientific Officer, Azitra. “Although NS is extremely rare, it is a severe, unmet need and patients are desperate for new treatment options. We hope to bring forward a novel, microbe-based therapy, AZT-02, to deliver missing proteins as a viable therapeutic strategy. This project demonstrates the versatility and importance of our microbe-based platform to deliver proteins to the skin.”
Azitra’s Chief Scientific Officer, Travis Whitfill and The Jackson Laboratory’s (JAX) skin microbiome expert, Julia Oh, are the principal investigators on this SBIR grant.
- Intermittent Fasting (IF) ameliorates the clinical course and pathology of the MS mouse model (EAE)
- IF increases gut microbial diversity, alters their composition and metabolic pathways
- Gut microbiota transfer from mice on IF led to protection from EAE in recipient mice
- Findings with IER in MS patients partially recapitulates what is observed with IF in EAE
A new paper in the journal Cell Metabolism shows that intermittent fasting (IF) can improve symptoms of multiple sclerosis, and that the effects are likely due to changes in the gut microbiota. George Weinstock and Yanjiao Zhou of The Jackson Laboratory were among the microbiome experts involved in the research.
“The microbes that live on our skin come into direct contact with myriad things from our environment — toxins, chemicals, other microbes — and they interact with molecules produced by our own cells to help maintain a healthy first line of defense against the outside world.”